Verastem filed a new-drug application seeking full approval from the FDA for duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, plus accelerated approval for relapsed/refractory follicular lymphoma. Verastem's filing includes data from its DUO trial, which showed duvelisib diminished the risk of disease progression or death by 48% compared with Arzerra, or ofatumumab, in patients with relapsed/refractory CLL/SLL, and the DYNAMO study, in which the drug showed an overall response rate of 41% in patients with follicular lymphoma.
Verastem seeks FDA approval for lymphoma drug candidate
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.